Matthew T. McKenna

Matthew T. McKenna

Auto-generated profile, based on publicly available information

Matthew T. McKenna

Institute of Imaging Science, Vanderbilt University, Nashville, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2018 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
AJAngela Jarrett
Angela Jarrett
ELErnesto A.B.F. Lima
Ernesto A.B.F. Lima
DIDavid A. Hormuth, II
David A. Hormuth, II
MMMatthew T. McKenna
Matthew T. McKenna
XFXinzeng Feng
Xinzeng Feng
TYThomas Yankeelov
Thomas Yankeelov
Introduction: A defining hallmark of cancer is aberrant cell proliferation. Efforts to understand the generative properties of cancer cells span all biological scales: from genetic deviations and alterations of metabolic pathways, to physical stresses due to overcrowding, as well as the effects of therapeutics and the immune system. While these factors have long been studied in the laboratory, mathematical and computational techniques are being increasingly applied to help understand and forecast tumor growth and treatment response. Advantages of mathematical modeling of proliferation include the ability to simulate and predict the spatiotemporal development of tumors across multiple experimental scales. Central to proliferation modeling is the incorporation of available biological data and validation with experimental data. Areas covered: We present an overview of past and current mathematical strategies directed at understanding tumor cell proliferation. We identify areas for mathematical development as motivated by available experimental and clinical evidence, with a particular emphasis on emerging, non-invasive imaging technologies. Expert commentary: The data required to legitimize mathematical models are often difficult or (currently) impossible to obtain. We suggest areas for further investigation to establish mathematical models that more effectively utilize available data to make informed predictions on tumor cell proliferation.

6 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AJAngela Jarrett
Angela Jarrett
ASAlay Shah
Alay Shah
MBMeghan J. Bloom
Meghan J. Bloom
MMMatthew T. McKenna
Matthew T. McKenna
DIDavid A. Hormuth, II
David A. Hormuth, II
ASAnna Sorace
Anna Sorace
The goal of this study is to experimentally and computationally investigate combination trastuzumab-paclitaxel therapies and identify potential synergistic effects due to sequencing of the therapies with in vitro imaging and mathematical modeling. Longitudinal alterations in cell confluence are reported for an in vitro model of BT474 HER2+ breast cancer cells following various dosages and timings of paclitaxel and trastuzumab combination regimens. Results of combination drug regimens are evaluated for drug interaction relationships based on order, timing, and quantity of dose of the drugs. Altering the order of treatments, with the same total therapeutic dose, provided significant changes in overall cell confluence (p < 0.001). Two mathematical models are introduced that are constrained by the in vitro data to simulate the tumor cell response to the individual therapies. A collective model merging the two individual drug response models was designed to investigate the potential mechanisms of synergy for paclitaxel-trastuzumab combinations. This collective model shows increased synergy for regimens where trastuzumab is administered prior to paclitaxel and suggests trastuzumab accelerates the cytotoxic effects of paclitaxel. The synergy derived from the model is found to be in agreement with the combination index, where both indicate a spectrum of additive and synergistic interactions between the two drugs dependent on their dose order. The combined in vitro results and development of a mathematical model of drug synergy has potential to evaluate and improve standard-of-care combination therapies in cancer.

1 April 2006 in AIDS Patient Care and STDs
Verified
Journal Article
Closed access
KMKathleen McDavid
Kathleen McDavid
MMMatthew T. McKenna
Matthew T. McKenna
Ascertainment of risk factors for HIV transmission is critical to monitoring the HIV epidemic. Since 1993, there has been an increase in the proportion of HIV/AIDS cases that are reported to the Centers for Disease Control and Prevention (CDC) without an identified risk factor for HIV. About this time many areas implemented laboratory reporting, which generates an initial report with little to no HIV risk factor information. In 2001, the CDC convened a group of experts who recommended changes to the presentation of HIV risk factor data. The CDC subsequently funded two projects to improve the collection of HIV risk factors by surveillance staff. Since 2004, the CDC and state surveillance coordinators revised surveillance guidance to recommend prioritization of follow-up and provider training, and to monitor key variables while providing feedback to reporters. The CDC also began an evaluation of provider-targeted educational materials. The CDC has also been working with professional associations to incorporate methods for documenting HIV risk factors into existing training modules. CDC and state surveillance coordinators will need to continue efforts to educate, train, and identify barriers for providers in order to improve the completeness of HIV risk factor documentation and reporting.

19 February 2021 in Journal of Medical Imaging
Verified
Journal Article
Closed access
PDF file
YYYiyuan Yang
Yiyuan Yang
YTYucheng Tang
Yucheng Tang
RGRiqiang Gao
Riqiang Gao
SBShunxing Bao
Shunxing Bao
YHYuankai Huo
Yuankai Huo
BLBennett A. Landman
Bennett A. Landman
Purpose: Deep learning is a promising technique for spleen segmentation. Our study aims to validate the reproducibility of deep learning-based spleen volume estimation by performing spleen segmentation on clinically acquired computed tomography (CT) scans from patients with myeloproliferative neoplasms. Approach: As approved by the institutional review board, we obtained 138 de-identified abdominal CT scans. A sum of voxel volume on an expert annotator’s segmentations establishes the ground truth (estimation 1). We used our deep convolutional neural network (estimation 2) alongside traditional linear estimations (estimation 3 and 4) to estimate spleen volumes independently. Dice coefficient, Hausdorff distance, R2 coefficient, Pearson R coefficient, the absolute difference in volume, and the relative difference in volume were calculated for 2 to 4 against the ground truth to compare and assess methods’ performances. We re-labeled on scan–rescan on a subset of 40 studies to evaluate method reproducibility. Results: Calculated against the ground truth, the R2 coefficients for our method (estimation 2) and linear method (estimation 3 and 4) are 0.998, 0.954, and 0.973, respectively. The Pearson R coefficients for the estimations against the ground truth are 0.999, 0.963, and 0.978, respectively (paired t-tests produced p < 0.05 between 2 and 3, and 2 and 4). Conclusion: The deep convolutional neural network algorithm shows excellent potential in rendering more precise spleen volume estimations. Our computer-aided segmentation exhibits reasonable improvements in splenic volume estimation accuracy.

10 November 2022 in Journal of Mathematical Biology
Verified
Journal Article
Closed access
PDF file
ARAnna Claudia M. Resende
Anna Claudia M. Resende
ELErnesto Augusto Bueno da Fonseca Lima
Ernesto Augusto Bueno da Fonseca Lima
RARegina Almeida
Regina Almeida
MMMatthew T. McKenna
Matthew T. McKenna
TYThomas Yankeelov
Thomas Yankeelov